The UBV-01N vaccine is Uganda’s first locally developed COVID-19 vaccine, created by scientists from Natural Chemotherapeutics Research Institute (NCRI), Makerere Lung Institute in collaboration with Uganda Virus Research Institute (UVRI) and other partners. It is a therapeutic vaccine candidate designed to boost the immune response in individuals exposed to the virus. The vaccine has undergone early-stage clinical trials to assess its safety, immunogenicity, and efficacy. UBV-01N is a significant milestone in Uganda’s efforts to strengthen its capacity for vaccine development and production, contributing to the global fight against the COVID-19 pandemic.